Clinical research OSA treatment, respectively ðP < 0:01Þ. OSA treatment significantly reduced the risk q Presented in part at the European Society of Cardiology Congress,

ow nloaded from doi:10.1016/j.ehj.2004.03.008.of occurrence of the composite endpoint (hazard ratio 0.24; 95 % confidence interval, 0.09–0.62; p < 0:01) and of each of its components. Conclusions Our data indicate that the treatment of OSA in CAD patients is associated with a decrease in the occurrence of new cardiovascular events, and an increase in the time to such events.c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.Aim The aim of this long-term prospective study was to evaluate the effect of treating obstructive sleep apnoea (OSA) on the rate of cardiovascular events in coronary artery disease (CAD). Methods and results We prospectively studied 54 patients (mean age 57.3 10.1 years) with both CAD (P70 % coronary artery stenosis) and OSA (apnoea–hypopnoea index P15). In 25 patients, OSA was treated with continuous positive airway pressure ðn 21Þ or upper airway surgery ðn 4Þ; the remaining 29 patients declined treat-ment for their OSA. The median follow-up was 86.5 39 months. The two groups wer